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Abstract: Hyaluronan (HA), a long-chain polysaccharide, is currently being evaluated as 
a potential therapeutic agent for a number of inﬂ  ammatory disorders. The effect of HA on 
inﬂ  ammation appears to be related to its molecular size, with larger polysaccharide chains 
having anti-inﬂ  ammatory activity and smaller ones having proinﬂ  ammatory properties. This 
dichotomous behavior is particularly relevant to the work of our laboratory on an aerosolized 
preparation of HA to treat pulmonary emphysema. The breakdown of inhaled HA into smaller 
fragments could possibly induce an inﬂ  ammatory reaction in the lung that counteracts any 
beneﬁ  cial effect. Consequently, the proposed therapeutic use of HA will require development 
of treatment strategies aimed at minimizing its proinﬂ  ammatory activity.
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Introduction
In terms of understanding the pathogenesis of pulmonary emphysema, the use of 
papain to experimentally induce the disease represented an initial breakthrough (Gross 
et al 1964). Originally intended as a possible treatment for interstitial pulmonary 
ﬁ  brosis, intratracheal instillment of papain instead produced emphysematous changes 
in the lung. This ﬁ  nding had added signiﬁ  cance because it came at a time when the 
relationship between alpha-1-antiproteinase deﬁ  ciency and pulmonary emphysema 
was just being recognized (Laurell and Eriksson 1963). Both observations empha-
sized the importance of proteolysis as a cause of the disease. An imbalance between 
lung proteases and their inhibitors was hypothesized to be responsible for the air-
space enlargement that characterizes pulmonary emphysema (Janoff 1985; Senior 
and Kuhn 1988). It was proposed that excess elastase activity caused damage to the 
elastic ﬁ  ber network of the lung, leading to dilatation and rupture of alveoli, reduced 
gas-exchange, and eventual respiratory failure.
The proteinase-antiproteinase concept of pulmonary emphysema served to focus 
research on the role of elastases with the hope that inhibiting the activity of these 
enzymes would prevent lung injury. This treatment strategy assumed, however, that 
emphysema was caused by a single abnormality; namely, excess elastase activity. If 
the disease represented a more general response of the lung to a variety of insults, 
then enzyme inhibition might have only limited efﬁ  cacy.
With this in mind, our laboratory has studied the possible use of aerosolized 
hyaluronan (HA) to directly protect lung elastic ﬁ  bers from injury (Cantor et al 1998; 
Cantor et al 2000, 2005). HA, a long-chain polysaccharide, has been shown to pref-
erentially bind to elastic ﬁ  bers, prevent elastolysis, and limit air-space enlargement 
in experimental models of emphysema induced by either porcine pancreatic elastase, 
human neutrophil elastase, or chronic exposure to cigarette smoke (Figure 1) (Cantor 
et al 1998, 2000, 2005). Since elastic ﬁ  ber breakdown may be a ﬁ  nal common pathway International Journal of COPD 2007:2(3) 284
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in pulmonary emphysema, this form of treatment might be 
effective against a number of agents capable of causing the 
disease, including various oxidants present in air pollutants 
and cigarette smoke.
Special properties of HA
As a constituent of the extracellular matrix, HA acts to stabilize 
proteoglycans and also contributes to tissue growth and repair 
(Toole 1981; Heinegard and Paulsson 1984). In particular, 
HA has been shown to be a critical component in amphibian 
limb regeneration, strongly inﬂ  uencing the initial stages of the 
process (Toole and Gross 1971). One of the main functions of 
HA may be to reduce cellular cohesion, thereby facilitating the 
restructuring of tissues (Toole and Gross 1971).
Production of HA is greatly elevated following experi-
mental induction of both emphysema and interstitial ﬁ  brosis 
(Karlinsky 1982; LaFuma et al 1985; Bray et al 1991). The 
increases observed in both diseases occur shortly after initia-
tion of lung injury. In the case of interstitial ﬁ  brosis, damage 
to alveolar lining cells results in marked epithelial (type II cell) 
hyperplasia and subsequent lung remodeling, both of which 
are associated with HA synthesis (Cantor et al 1989).
Since cell proliferation is not characteristic of pulmonary 
emphysema, the role of HA in this disease may depend more 
upon its interactions with other matrix components than its 
capacity to enhance tissue growth. Several studies suggest 
that HA and other glycosaminoglycans form a network 
which surrounds elastic ﬁ  bers (Baccarani-Contri et al 1990; 
Bray et al 1994). Thus, the increased HA synthesis follow-
ing emphysematous injury could prevent further damage to 
elastic ﬁ  bers and perhaps facilitate their repair.
More recently, HA has been found to play an important 
role in inﬂ  ammation. The inﬂ  ammatory activity of HA is 
related to its molecular weight, which can vary in tissues 
from thousands to millions of daltons. Low molecular weight 
fragments accumulate at sites of inﬂ  ammation, and are known 
to stimulate the production of a variety of cytokines (McKee 
et al 1996; Horton et al 1999; Mascarenhas et al 2004). 
Conversely, high molecular weight HA fragments possess 
anti-inﬂ  ammatory properties, and may also promote repair 
of tissues (Moreland 2003; Noble and Jiang 2006).
The proinﬂ  ammatory potential of HA may be related 
to its afﬁ  nity for the CD44 receptor, an 85 kDa cell surface 
glycoprotein that is expressed by a variety of cell types. 
Interactions between endothelial cell HA and leukocyte 
CD44 receptors facilitate the extravasation of inﬂ  ammatory 
cells at sites of injury (Calkins et al 2001; Wang et al 2002; 
Kipnis et al 2003; Khan et al 2004). Furthermore, the binding 
of HA to macrophage CD44 receptors induces transcription 
of proinﬂ  ammatory genes (McKee et al 1996).
The anti-inﬂ  ammatory activity of HA may be equally 
potent, but is less well understood. The mechanisms respon-
sible for the mitigation of inﬂ  ammation by HA may depend 
not only on direct interaction with inﬂ  ammatory cells, but on 
the physical properties of the molecule itself. By virtue of its 
strongly anionic nature (due to negatively charged carboxyl 
groups), HA can retain relatively large amounts of water.
The ability of HA to expand its domain in a ﬂ  uid environ-
ment may have a number of consequences for tissue reac-
tions. By creating a more viscous milieu, HA may impede 
the movement of cells and molecules through the extracel-
lular matrix, thereby reducing the activity of leukocytes and 
their proinﬂ  ammatory products. The consequences of this 
“physical barrier” effect of HA have been explored in our 
laboratory, where introduction of exogenous HA into the 
lung has been shown to slow the progression of lung injury 
in several animal models of pulmonary emphysema.
Figure 1 (Upper) Mouse lung exposed to cigarette smoke for 3 months shows 
signiﬁ  cant airspace enlargement. (Lower) Mouse lung treated with aerosolized HA 
during the same 3-month period of smoke exposure shows only minimal airspace 
enlargement.International Journal of COPD 2007:2(3) 285
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Aerosolized HA in experimental 
lung injury
Pulmonary emphysema
The conceptual basis for using nebulized HA to treat pul-
monary emphysema developed from a series of animal 
experiments designed to determine whether agents other 
than elastases were capable of inducing or enhancing pulmo-
nary emphysema. A nonelastolytic enzyme, hyaluronidase, 
was shown to produce pulmonary airspace enlargement in 
hamsters when administered in conjunction with 60 percent 
oxygen (Cantor et al 1993). Damage to elastic ﬁ  bers occurred 
only when both agents were given concomitantly, suggesting 
the possibility that hyaluronidase may facilitate the break-
down of these ﬁ  bers by making them more accessible to in-
jury. This hypothesis was also tested in studies demonstrating 
that hyaluronidase enhances airspace enlargement in a well-
established model of emphysema induced by intratracheal 
administration of elastase (Cantor et al 1995).
Experiments were then undertaken to examine the effect 
of low molecular weight (150 kDa) HA itself on this model. 
Animals treated with aerosolized HA prior to instillation of 
elastase showed signiﬁ  cantly less airspace enlargement than 
controls treated with elastase alone (Cantor et al 1998, 2000). 
The exogenous HA preferentially adhered to elastic ﬁ  bers, 
suggesting that it may protect these ﬁ  bers from enzymatic 
breakdown (Figure 2) (Cantor et al 1998, 2000).
To determine if HA could actually prevent elastolysis, 
radiolabeled elastic ﬁ  bers, derived from rat pleural mesothe-
lial cells, were used as a test substrate (Cantor et al 2000). 
Coating the ﬁ  bers with HA signiﬁ  cantly decreased elastoly-
sis induced by several different types of elastase, including 
human neutrophil elastase and human metalloproteinase.
In addition to protecting elastic ﬁ  bers from enzymatic 
breakdown, exogenously administered HA may also prevent 
air-space enlargement by increasing the water content of the 
extracellular matrix. Since the distensibility of elastic ﬁ  bers 
is dependent on interactions with water molecules, addition 
of HA may improve the mechanical properties of these 
ﬁ  bers, thereby preventing alveolar dilatation and rupture 
(Wasserman and Salemme 1990; Mariani et al 1997; Li et al 
2001; Cantor et al 2004).
Airway hyperreactivity
While our laboratory has concentrated on the use of HA to 
treat emphysematous lung injury, other investigators have 
demonstrated a beneﬁ  cial effect of this agent in animal 
models of airway hyperreactivity. When aerosolized HA was 
given to sheep, it signiﬁ  cantly reduced bonchoconstriction 
due to inhalation of either neutrophil or pancreatic elas-
tase (Scuri et al 2001; Scuri and Abraham 2003). In both 
cases, increasing the molecular weight of HA enhanced its 
effectiveness.
The mechanism of action of HA in preventing broncho-
constriction may involve an afﬁ  nity for tissue kallikrein, 
which could reduce kinin-mediated inﬂ  ammatory reactions 
in airway walls (Forteza et al 1999). The increased ability 
of higher molecular weight HA to prevent bronchoconstric-
tion might therefore reﬂ  ect a greater capacity for binding 
kallikrein.
More recently, aerosolized HA was shown to prevent 
exercise-induced bronchoconstriction in asthmatic patients 
(Petrigni and Allegra 2006). Here again, the molecular weight 
of HA may play a critical role, as evidenced by the fact that 
Figure 2 HA is a long-chain polysaccharide composed of repeating disaccharide 
units of glucuronic acid and n-acetylglucosamine. When administered intratrache-
ally, it binds to alveolar septal elastic ﬁ  bers and may prevent their degradation by 
elastases released from macrophages and neutrophils.
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another study using smaller-sized HA showed no protective 
effect (Kunz et al 2006).
Acute lung injury
Although previous studies from this laboratory indicated that 
administration of our preparation of HA was not associated 
with pulmonary inﬂ  ammation, other investigators have found 
that low-molecular weight HA may be proinﬂ  ammatory 
(McKee et al 1996; Horton et al 1999; Mascarenhas 2004). 
This prompted us to determine if aerosolized HA could 
possibly enhance inﬂ  ammation in a more fulminant type of 
lung injury.
Using an experimental model involving intratracheal 
instillation of endotoxin (Yasui et al 1995), we tested the 
effects of HA on the acute inﬂ  ammatory response (Nadkarni 
et al 2005). Animals were given aerosolized HA either imme-
diately before or after administration of endotoxin, and studied 
over the next 24-hours. The results indicate that treatment with 
HA following endotoxin instillation enhanced lung inﬂ  amma-
tion whereas pretreatment had the opposite effect.
This dichotomous response was reﬂ  ected by measure-
ment of several parameters of lung injury, including histogi-
cal evidence of inﬂ  ammation, bronchoalveolar (BAL) cell 
content, TNFR1 expression on BAL macrophages, and lung 
apoptosis. Administration of aerosolized HA immediately 
before instillation of endotoxin signiﬁ  cantly reduced all of 
these inﬂ  ammatory markers compared to controls treated 
with endotoxin alone. Conversely, treatment with HA fol-
lowing endotoxin instillation signiﬁ  cantly increased all of the 
markers compared to endotoxin administration alone.
The proinflammatory effects of HA following 
endotoxin instillation may possibly involve alterations 
in the rate of leukocyte migration into the lung. By bind-
ing to CD44 receptors on the surface of neutrophils, the 
exogenous HA may reduce the interaction of these cells 
with the surrounding extracellular matrix and accelerate 
their inﬂ  ux into airspaces (Calkins et al 2001; Wang et al 
2002; Kipnis et al 2003; Khan et al 2004). Furthermore, 
increased expression of TNFR1 on macrophages may 
enhance TNF-alpha-induced secretion of enzymes that 
degrade HA into smaller fragments, thereby triggering the 
release of cytokines that amplify lung injury (McKee et al 
1996). Enhanced expression of TNFR1 may also account 
for the increased apoptosis seen in the lungs of animals 
post-treated with HA (Alikhani et al 2004).
In contrast, pre-exposure to HA may decrease endotoxin-
induced inﬂ  ammation by limiting cell-cytokine interactions. 
For example, HA could bind to macrophage CD44 receptors, 
coat the cell surface, and block the attachment of TNF-alpha, 
thus preventing activation of various proinﬂ  ammatory genes 
(Figure 3).
Although the HA used in our experiments had a relatively 
low molecular weight, it nevertheless exhibited anti-
inﬂ  ammatory activity when administered prior to endotoxin. 
This could possibly be explained by the self-aggregating 
properties of this molecule (Scott et al 1991). Aerosolized 
HA deposited in the lung interstitium prior to endotoxin 
instillation may form larger complexes that exhibit the same 
anti-inﬂ  ammatory activity as high-molecular weight HA. 
When administered after endotoxin administration, however, 
HA might immediately be broken down and never form such 
complexes.
Maximizing the therapeutic 
potential of HA
The results of the experiments with endotoxin indicate that 
HA may be a double-edged sword with regard to its therapeu-
tic efﬁ  cacy. In the absence of underlying inﬂ  ammation, HA 
may exert a beneﬁ  cial effect, as both an anti-inﬂ  ammatory 
agent and a protective barrier against the degradative activi-
ties of various inﬂ  ammatory products. Conversely, the pres-
ence of a pre-existing inﬂ  ammatory milieu has the potential 
to convert HA into a proinﬂ  ammatory mediator and thereby 
counteract its therapeutic activity.
Further clinical testing of aerosolized HA should there-
fore involve frequent measurement of inﬂ  ammatory markers. 
These might include differential cell counts in bronchoalveo-
lar lavage ﬂ  uid, sputum and plasma levels of proinﬂ  ammatory 
cytokines, and markers of proteinase activity, such as plasma 
ﬁ  bronogen fragments (Stolk et al 2005). The results of these 
studies could then be used to determine a dosing schedule for 
HA that minimizes the risk of an inﬂ  ammatory response.
Since HA can break down into smaller, proinﬂ  ammatory 
fragments, increasing its initial molecular weight might also 
reduce the possibility of further lung injury. The use of 500 kDa 
HA, instead of a 150 kDa preparation, could limit the formation 
of proinﬂ  ammatory, low-molecular weight fragments.
However, any increase in molecular weight would have to 
be weighed against possible changes in therapeutic efﬁ  cacy. 
Large molecules such as HA do not readily penetrate the 
alveolar epithelial barrier. Consequently, the dosage size and 
frequency of administration of HA will need to be carefully 
titrated to prevent its accumulation in alveolar spaces, where 
it can be broken down into smaller fragments. Measuring the 
clearance rate of HA from the lung could help determine the 
optimum dosing schedule.International Journal of COPD 2007:2(3) 287
Therapeutic applications of HA
The physical form in which HA is administered might 
also affect its therapeutic efﬁ  cacy. The use of a dry powder 
instead of a solution, or addition of a carrier molecule, might 
limit the breakdown of HA in the lung. Alternatively, it 
may be possible to modify the molecular structure of HA to 
reduce its proinﬂ  ammatory potential while mainintaining its 
protective effects.
Conclusion
The use of nebulized HA as a potential treatment for pulmonary 
emphysema represents a different approach to treating disease 
– one that is directed toward the extracellular matrix rather than 
intracellular processes. The proposed mechanisms of action of 
HA discussed in this paper may have broad applicability to a 
number of other conditions involving injury to extracellular 
matrix components, including osteoarthritis (which is already 
being treated with exogenous HA), vascular aneurysms, and 
skin aging (Moreland 2003; Gandhi et al 1994; Fisher et al 
1997). However, exploiting the therapeutic potential of HA 
will require a greater understanding of the complex relationship 
between this molecule and the inﬂ  ammatory process. Such 
insight may not only advance the use of HA as a treatment for 
a variety of diseases, but also facilitate the development of a 
whole new class of agents designed to protect the extracellular 
matrix against the damaging effects of inﬂ  ammation.
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